Analyst Group: Analyst Group Comment on Genetic Analysis Q2-report Report 2025
Genetic Analysis AS (“Genetic Analysis” or the “Company”) published on August 27th the Company’s Q2-report for 2025.
The following are some key points that we have chosen to highlight in connection with the report:
- Strong sales growth through reagent kit sales in USA
- Improved EBITDA-result through solid gross margin and cost control
- Strengthened cash position though rights issues for further commercial investments
- Launch of GA-map® MHI GutHealth in the USA
In summary, Genetic Analysis delivered strong progress in Q2-25 with sales growth of 34%, primarily driven by strong demand for reagent kits in the U.S., validating the Company’s scalable business model and the growing global focus on microbiome diagnostics. The commercial rollout of the GA-map® platform through new partner laboratories, the launch of a consumer health test in China with Thalys, and the recent introduction of GA-map® MHI GutHealth in the U.S. provide multiple growth drivers going forward. Despite tariff-related headwinds temporarily affecting gross margins, underlying profitability remains supported by high-margin reagent kits and strong cost control, with operating expenses down 33% Y-Y, paving the way for further profitability improvements going forward.
Read Analyst Group’s comment on the report here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.